Compare NCRA & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCRA | SBFM |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 6.0M |
| IPO Year | 2022 | N/A |
| Metric | NCRA | SBFM |
|---|---|---|
| Price | $0.20 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 416.0K | 30.2K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.26 |
| Revenue Next Year | N/A | $32.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $1.00 |
| 52 Week High | $2.40 | $2.43 |
| Indicator | NCRA | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 30.84 | 42.07 |
| Support Level | $0.18 | N/A |
| Resistance Level | $0.32 | $1.52 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 15.48 | 22.49 |
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.